Michelle Gilson
Stock Analyst at Morgan Stanley
(1.15)
# 3,465
Out of 4,784 analysts
31
Total ratings
32.14%
Success rate
-6.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $6.70 | +198.51% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $54.63 | -45.09% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $2.93 | +480.20% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $154.68 | +26.71% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $19.68 | +128.66% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $7.21 | +954.09% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $71.44 | +27.38% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $6.70
Upside: +198.51%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $54.63
Upside: -45.09%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $2.93
Upside: +480.20%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $154.68
Upside: +26.71%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $19.68
Upside: +128.66%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $7.21
Upside: +954.09%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $71.44
Upside: +27.38%